ClinPro And GCP Clinical Studies Ltd. Join In Strategic Alliance; Global Clinical Trial Organization Aligns With Israel's Six Largest Cancer Treatment Centers To Conduct Oncology Trials
10/19/2005 5:12:16 PM
BOUND BROOK, N.J.--(BUSINESS WIRE)--Jan. 13, 2005--ClinPro, Inc., a full-service clinical research organization (CRO), today announced the formation of a strategic alliance between ClinPro's Center for Oncology Research Management (CORM) and GCP Clinical Studies Ltd., a leading provider of clinical research services and education programs in Israel. GCP Clinical Studies will support the conduct of oncology clinical trials at the six largest cancer treatment centers in Israel. The ClinPro presence in Israel is in line with the Company's strategy to expand its global clinical research capabilities working with local medical and monitoring personnel to support the company's work with industry-sponsored clinical oncology trials. The association between CORM and the Israeli Cancer Centers is designed to eliminate some of the bottlenecks that have traditionally led to inefficiencies in the clinical trial process. "One of the biggest hurdles in clinical development of cancer drugs is the intense competition for patients willing and able to participate in clinical trials - particularly in Phase I studies," says Howard Goldsweig, MD, ClinPro vice president of medical affairs. "To address the issue, ClinPro's Center for Oncology Research Management (CORM) is pursuing a strategy of expanded access to qualified investigational sites outside the U.S." Among Israel's population of 6.7 million, there were 22,300 newly diagnosed cases of cancer recorded in 2001. Because of Israel's sophisticated clinical and research infrastructures, the U.S. Food and Drug Administration (FDA) recognizes clinical trial data contributed by Israeli investigators.
comments powered by